SCHEMBL23723623

SCHEMBL23723623

Cc1ccc(NC(=O)CN(C)Cc2nc3c(cnn3C)c(=O)[nH]2)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 6/20 0.61
MEN1 O00255 3/20 0.61
MAPK1 P28482 1/20 0.61
ALDH1A1 P00352 6/20 0.47
HPGD P15428 1/20 0.47
LMNA P02545 3/20 0.45
HTT P42858 2/20 0.45
ATM Q13315 1/20 0.45
ALPL P05186 1/20 0.43
ALPI P09923 1/20 0.43
CYP1A2 P05177 2/20 0.41
CYP2C9 P11712 2/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2D6 P10635 1/20 0.41
NPC1 O15118 1/20 0.40
MITF O75030 1/20 0.40
POLB P06746 1/20 0.40
THRB P10828 1/20 0.40
RAB9A P51151 1/20 0.40
CASP6 P55212 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23723639 0.91 ALDH1A1 (0.52) KMT2AMEN1MAPK1ALDH1A1HPGD
SCHEMBL23723719 0.87 KMT2A (0.49) KMT2AMEN1MAPK1ALDH1A1HPGD
SCHEMBL30368715 0.84 KMT2A (0.45) KMT2AMEN1MAPK1ALDH1A1HPGD
SCHEMBL23723548 0.84 ALDH1A1 (0.56) KMT2AMEN1MAPK1ALDH1A1HPGD
SCHEMBL23723853 0.80 TNKS (0.40) KMT2AMEN1MAPK1ALDH1A1LMNA
SCHEMBL23723513 0.78 KMT2A (0.41) KMT2AMEN1MAPK1ALDH1A1HPGD
SCHEMBL23723704 0.76 KMT2A (0.42) KMT2AMEN1ALDH1A1LMNAHTT
SCHEMBL23749881 0.76 TNKS (0.47) KMT2AALDH1A1HPGDLMNAALPL
SCHEMBL23723707 0.75 TNKS (0.42) KMT2AMEN1ALDH1A1LMNAALPL
SCHEMBL30132053 0.75 TNKS (0.42) KMT2AMEN1ALDH1A1LMNAALPL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230140216-A1 COMBINATION THERAPY FOR TREATING MPS1 GAIN THERAPEUTICS SA (CH) 2023-05-04 US disclosed
US-20230140216-A1 COMBINATION THERAPY FOR TREATING MPS1 GAIN THERAPEUTICS SA (CH) 2023-05-04 US disclosed
US-20230140216-A1 COMBINATION THERAPY FOR TREATING MPS1 GAIN THERAPEUTICS SA (CH) 2023-05-04 US disclosed
EP-4100015-A1 COMBINATION THERAPY FOR TREATING MPS1 Gain Therapeutics SA (CH) 2022-12-14 EP disclosed
CN-115397423-A Combination therapy for the treatment of MPS1 增益治疗股份有限公司 2022-11-25 CN disclosed
WO-2021156774-A1 COMBINATION THERAPY FOR TREATING MPS1 GAIN THERAPEUTICS SA (CH) 2021-08-12 WO disclosed
WO-2021156774-A1 COMBINATION THERAPY FOR TREATING MPS1 GAIN THERAPEUTICS SA (CH) 2021-08-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230140216-A1 COMBINATION THERAPY FOR TREATING MPS1 IDUA, MAN2B1, GBA1 KMT2A 3761/4885MEN1 1434/4885MAPK1 4151/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.